Optimizing the timing of JAK1 inhibition preserves the anti-tumor efficacy of radioimmunotherapy in lung cancer by preventing T cell exhaustion.

Although concurrent administration of the JAK1 inhibitor with iRT appeared to diminish the anti-tumor efficacy upon gross observation, the differences in tumor volume and weight between groups did not reach statistical significance (Fig.

also in 111,027 other papers